<DOC>
	<DOCNO>NCT01919229</DOCNO>
	<brief_summary>This multi-center , open-label Phase II randomize pre-surgical pharmacodynamics study .</brief_summary>
	<brief_title>A Pharmacodynamics Pre-surgical Study LEE011 Early Breast Cancer Patients ( MONALEESA-1 )</brief_title>
	<detailed_description>This randomize pre-surgical pharmacodynamics study assess biological activity LEE011 plus letrozole versus single agent letrozole primary breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Female patient ≥ 18 year old time inform consent , newly diagnose resectable breast cancer , receive prior therapy breast cancer Patient postmenopausal . Postmenopausal status define either : Prior bilateral oophorectomy Age ≥60 Age &lt; 60 amenorrhea 12 month FSH ( Follicle Stimulating Hormone ) estradiol postmenopausal range . Patient histologically ( and/or cytologically ) confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive breast cancer local laboratory . Patient grade II grade III invasive breast cancer Patient Human Epidermal Growth Factor Receptor 2 ( HER2 ) negative breast cancer define negative situ hybridization test Immunohistochemistry ( IHC ) status 0 , 1+ 2+ ( IHC 2+ , negative situ hybridization ( respectively FISH/CISH/SISH ) test require ) local laboratory test Patient least one breast lesion diameter ≥1.0 cm accurate image modality use . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient receive prior therapy breast cancer . Patient concurrent malignancy malignancy within 3 year randomization , exception adequately treat , basal cell skin cancer squamous cell carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer . Patient active cardiac disease history cardiac dysfunction include follow : History angina pectoris , symptomatic pericarditis , myocardial infarction within 12 month prior study entry History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Documented cardiomyopathy Patient Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) History ventricular , supraventricular , nodal arrhythmia , cardiac arrhythmia , Long QT Syndrome conduction abnormality previous 12 month . Family history QTc prolongation unexplainable sudden death &lt; 50 year age . On screen 12 lead ECG , follow cardiac parameter : bradycardia ( heart rate &lt; 50 rest ) , tachycardia ( heart rate &gt; 90 rest ) , PR interval &gt; 220 msec , QRS interval &gt; 109 msec , QTcF &gt; 450 msec . Systolic blood pressure &gt; 160 mmHg &lt; 90 mmHg . Patient currently receive follow medication ( see Appendix 1 detail ) : That know strong inducer inhibitor CYP3A4 . That narrow therapeutic window predominantly metabolize CYP3A4 . That know risk prolong QT interval induce Torsades de Pointes . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>LEE011</keyword>
	<keyword>Letrozole</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pre-surgical</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>